Compare Gilead Sciences, Inc. (GILD) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Verizon Communications Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Verizon Communications Inc trades at $41.65 (market cap $192.57B). The key difference: Gilead Sciences, Inc. and Verizon Communications Inc are close in size by market cap, and Verizon Communications Inc pays the higher dividend (6.11%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Verizon Communications Inc for 109 Days on average.
| GILD | VZ | |
|---|---|---|
Market Cap | $182.40B | $192.57B |
Volume | 4,469,821 | 20,940,094 |
Sector | Health | Media |
52-Week High | $155.80 | $51.45 |
52-Week Low | $117.18 | $38.40 |
Typical Hold Time | 111 Days | 109 Days |
Enterprise Value | $205.46B | $379.28B |
Dividend Yield | 2.23% | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Verizon (VZ) trades at $46.35, up 1.27% today, with a bearish technical signal but strong fundamentals including a P/E of 12.07 and net income margin of 11.64%. Recent earnings beats and a $0.71 dividend highlight stability, while cash flow improved to $14.86B in 2025. The stock is near its consensus price target of $48.17, with analyst sentiment mixed but leaning hold.
Outlook: Verizon offers value with steady dividends and cash flow, but faces competition and debt risks. Upside depends on execution in wireless markets; cautious optimism is warranted given technical weakness and modest growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
